Outlook Therapeutics, INC Form 4 insider transactions

Robert Charles Jahr, Chief Executive Officer and a Director of Outlook Therapeutics, Inc., purchased 303,030 shares of common stock on August 14, 2026.

Ghiath M. Sukhtian and 1 other reported changes in beneficial ownership of Outlook Therapeutics, Inc. common stock on August 12, 2026.

Lawrence A Kenyon, Chief Financial Officer and a Director of Outlook Therapeutics, Inc., purchased 202,020 shares of common stock on August 14, 2026.

Faisal Ghiath Sukhtian, a Director of Outlook Therapeutics, Inc., purchased 95,398 shares of common stock on July 29, 2026 for $1.05 per share.

Lawrence A Kenyon, Chief Financial Officer and a Director of Outlook Therapeutics, Inc., received 210,078 shares of common stock on July 21, 2026.

Robert Charles Jahr, Chief Executive Officer and a Director of Outlook Therapeutics, Inc., received 100,000 shares of common stock on July 21, 2026.

Director Yezan Haddadin purchased 29,000 shares of Outlook Therapeutics, Inc. common stock at an average price of $0.8326.

GMS Ventures & Investments increases its stake in Outlook Therapeutics through a $5 million share purchase and a significant repricing of existing warrants.

Outlook Therapeutics, Inc. reports a Form 4 filing detailing a significant stock acquisition by Director Faisal Ghiath Sukhtian.

Outlook Therapeutics Director Yezan Munther Haddadin reported the acquisition of 34,000 common shares on May 26, 2026.

Outlook Therapeutics, Inc. Director Randy H. Thurman acquired 5,000 shares of common stock on May 26, 2026.

Outlook Therapeutics Director Kurt J. Hilzinger acquired 400,000 shares of common stock on May 26, 2026, at a price of $0.4413 per share.

Outlook Therapeutics director Andong Huang was granted 340,050 stock options under the company's 2024 Equity Incentive Plan and Non-Employee Director Compensation Policy.

Outlook Therapeutics Director Julia A. Haller received two grants of stock options totaling 345,382 shares as part of her compensation.

Outlook Therapeutics director Kurt J. Hilzinger was granted stock options for 377,372 shares of common stock as part of his compensation and the company's 2024 Equity Incentive Plan.

Outlook Therapeutics Director Julian S Gangolli received an annual stock option grant for 286,734 shares, vesting on October 1, 2026.

Outlook Therapeutics director Yezan Munther Haddadin acquired 382,703 stock options with exercise prices of $1.04 and $1.06, some in lieu of cash fees.

Outlook Therapeutics director Gerd Auffarth was granted 345,382 stock options with exercise prices of $1.04 and $1.06, vesting through September 2026.

Outlook Therapeutics Director Randy H. Thurman received an annual stock option grant of 286,734 shares with an exercise price of $1.04.

Outlook Therapeutics director Faisal Ghiath Sukhtian received two grants of stock options, totaling 404,030 shares, as part of his compensation package.

Outlook Therapeutics, Inc. has granted its Chief Executive Officer, Robert Charles Jahr, 800,000 stock options with an exercise price of $1.58, vesting over four years.

Ghiath M. Sukhtian and GMS Ventures & Investments, a director and 10% owner of Outlook Therapeutics, Inc., acquired over 4.2 million shares of common stock and 8.5 million warrants in a recent underwritten public offering at $1.40 per unit.

Ghiath M. Sukhtian, a director and 10% owner of Outlook Therapeutics, amends a previous filing to accurately report the receipt of shares from warrant exercises and correct the transaction date.

Faisal Ghiath Sukhtian, a director of Outlook Therapeutics, acquired stock options exercisable for 12,323 shares of common stock on February 4, 2025.

Ghiath M. Sukhtian, a director and 10% owner of Outlook Therapeutics, reported transactions involving warrants, including acquisitions and exercises, as part of a warrant exercise inducement offer.

Director Julian S. Gangolli received stock options for Outlook Therapeutics, Inc. under the company's equity incentive plan.

Director Julia Haller received stock options from Outlook Therapeutics under the company's equity incentive plan and non-employee director compensation policy.

Director Andong Huang acquired stock options in Outlook Therapeutics, Inc. through grants under the company's equity incentive plan and non-employee director compensation policy.

Director Gerd Auffarth received multiple stock option grants from Outlook Therapeutics, vesting over the next year and expiring in 2034.

Director Yezan Munther Haddadin received multiple stock option grants from Outlook Therapeutics, vesting over the next year, according to a Form 4 filing.